212 related articles for article (PubMed ID: 36282806)
21. Insufficient Impact: Limited Implementation of Federal Regulatory Changes to Methadone and Buprenorphine Access in Arizona During COVID-19.
Meyerson BE; Bentele KG; Brady BR; Stavros N; Russell DM; Mahoney AN; Garnett I; Jackson S; Garcia RC; Coles HB; Granillo B; Carter GA
AJPM Focus; 2024 Apr; 3(2):100177. PubMed ID: 38312524
[TBL] [Abstract][Full Text] [Related]
22. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
Roy V; Buonora M; Simon C; Dooling B; Joudrey P
Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
[TBL] [Abstract][Full Text] [Related]
23. "Sign Me Up": a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic.
Darnton JB; Bhatraju EP; Beima-Sofie K; Michaels A; Hallgren KA; Soth S; Grekin P; Woolworth S; Tsui JI
Addict Sci Clin Pract; 2023 Mar; 18(1):21. PubMed ID: 36991506
[TBL] [Abstract][Full Text] [Related]
24. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
[TBL] [Abstract][Full Text] [Related]
25. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences.
McDonald R; Bech AB; Clausen T
BMC Health Serv Res; 2023 Sep; 23(1):965. PubMed ID: 37679751
[TBL] [Abstract][Full Text] [Related]
26. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
[TBL] [Abstract][Full Text] [Related]
27. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
28. Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore.
Abidogun TM; Cole TO; Massey E; Kleinman M; Greenblatt AD; Seitz-Brown CJ; Magidson JF; Belcher AM
J Subst Use Addict Treat; 2023 Feb; 145():208946. PubMed ID: 36880915
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.
Joudrey PJ; Kolak M; Lin Q; Paykin S; Anguiano V; Wang EA
JAMA Netw Open; 2022 Apr; 5(4):e227028. PubMed ID: 35438757
[TBL] [Abstract][Full Text] [Related]
30. Trajectories of drug treatment and illicit opioid use in the AIDS Linked to the IntraVenous Experience cohort, 2014-2019.
Rudolph JE; Cepeda JA; Astemborski J; Kirk GD; Mehta SH; Genberg BL
Int J Drug Policy; 2023 Aug; 118():104120. PubMed ID: 37429162
[TBL] [Abstract][Full Text] [Related]
31. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
[TBL] [Abstract][Full Text] [Related]
32. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G; Bruneau J; Cox N; Gordon AJ
Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
[TBL] [Abstract][Full Text] [Related]
33. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
[TBL] [Abstract][Full Text] [Related]
34. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
35. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
Harrington C; Bailey A; Delorme E; Hano S; Evans EA
Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
[No Abstract] [Full Text] [Related]
36. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
37. The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic.
Nesoff ED; Marziali ME; Martins SS
Addiction; 2022 Jun; 117(6):1781-1786. PubMed ID: 34873783
[TBL] [Abstract][Full Text] [Related]
38. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
[TBL] [Abstract][Full Text] [Related]
39. Treatment provider perceptions of take-home methadone regulation before and during COVID-19.
Madden EF; Christian BT; Lagisetty PA; Ray BR; Sulzer SH
Drug Alcohol Depend; 2021 Nov; 228():109100. PubMed ID: 34600251
[TBL] [Abstract][Full Text] [Related]
40. "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
Harris MTH; Lambert AM; Maschke AD; Bagley SM; Walley AY; Gunn CM
J Subst Abuse Treat; 2022 Apr; 135():108655. PubMed ID: 34772604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
